Session 40: Ovarian Stimulation 2

I-24: Individualized Controlled Ovarian Stimulation (iCOS)

Background: With the recent development of recombinant gonadotropins (FSH and LH), it has become possible to further adjust the stimulation protocol according to the expected needs of the patient. In this respect, the possible beneficial role of exogenous LH activity supplementation for stimulated ART cycles has received increasing attention. According to the two-cell, two- gonadotropin theory,...

I-32: Avoiding OHSS in Ovarian Stimulation

Multiple pregnancies and ovarian hyper stimulation syndrome (OHSS) are the most serious complications of ovarian stimulation and IVF. Indeed, they are more or less the only ones. OHSS can effectively be prevented in three stages: Before stimulation, during stimulation and at ET. Before stimulation patients should be assessed as to age, the ovarian follicular count and/or anti mullerian hormone ...

Session 2

Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation

Polycystic ovarian syndrome (PCOS) ovaries are characterized by increased angiogenesis and hypervascularity. While angiopoietin-1 (Ang-1) and its antagonist, angiopoietin-2 (Ang-2), are essential for ovarian function and angiogenesis, the levels of Ang-1 and Ang-2 in PCOS are unknown. This was a prospective cohort study of 14 PCOS women and 14 matched controls undergoing controlled ovarian stim...

I-37: Controlled Ovarian Stimulation in Cancer Patients

Recent advances in the technology of vitrification of human oocytes and embryos have increased the opportunities for fertility preservation in cancer patients. Ovarian stimulation in this group of patients is associated with some unique challenges. A controversy in this field rotated around the hypothesis that the transient elevations of estrogen during an IVF cycle may stimulate tumor growth; ...